Brief: Inozyme Pharma Announces Positive Preliminary Data From Phase 1/2 Clinical Trial Of INZ-701

Inozyme Pharma

19/07/2022 21:54

July 19 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES POSITIVE PRELIMINARY DATA FROM
PHASE
1/2 CLINICAL TRIAL OF INZ-701 IN SUBJECTS WITH ABCC6 DEFICIENCY
(PSEUDOXANTHOMA ELASTICUM OR PXE)
    * INOZYME PHARMA INC - INZ-701 WAS GENERALLY WELL-TOLERATED
AND
EXHIBITED A FAVORABLE INITIAL SAFETY PROFILE
    * INOZYME PHARMA INC - RAPID AND SIGNIFICANT INCREASE IN
PLASMA
PYROPHOSPHATE (PPI) LEVELS OBSERVED IN ALL THREE SUBJECTS IN
LOWEST DOSE COHORT
    * INOZYME PHARMA INC- DOSING IN SECOND DOSE COHORT (0.6
MG/KG)
EXPECTED TO COMMENCE IN Q3 OF 2022
    * INOZYME PHARMA INC- FIRST EVIDENCE THAT INZ-701 INCREASED
PPI
LEVELS IN SUBJECTS WITH FUNCTIONAL ENPP1 ENZYME
    * INOZYME PHARMA INC - PLANS TO REPORT TOPLINE DATA FROM
ONGOING
PHASE 1/2 CLINICAL TRIAL IN ABCC6 DEFICIENCY IN Q1 OF 2023

Source text for Eikon:  ID:nGNX9tg7JP 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))